# A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

> **NCT07402512** · PHASE3 · RECRUITING · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 498 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **DRUG:** SIM0916
- **DRUG:** SIM0916 Placebo

## Key facts

- **NCT ID:** NCT07402512
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 498 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07402512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07402512, "A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07402512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*